OncoMatch/Clinical Trials/NCT07410676
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Is NCT07410676 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies EBNK-001 + IL-15 + Pembrolizumab for cancer.
Treatment: EBNK-001 + IL-15 + Pembrolizumab — This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15, administered either alone or in combination with pembrolizumab in adults with advanced/metastatic solid tumors. The study will determine a recommended Phase 2 dose (RP2D) and explore signals of clinical activity using RECIST-based response criteria.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Sarcoma
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Colorectal Cancer
Melanoma
Urothelial Carcinoma
Renal Cell Carcinoma
Pancreatic Cancer
Hepatocellular Carcinoma
Ovarian Cancer
Esophageal Carcinoma
Glioblastoma
Disease stage
Required: Stage IV
Metastatic disease required
advanced/metastatic solid tumor; Measurable disease per RECIST v1.1 (or iRECIST if applicable)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard therapy
relapsed/refractory after standard therapy (or no standard therapy available)
Cannot have received: investigational agent
Receipt of investigational agent within 28 days before first study drug
Lab requirements
Blood counts
platelets ≥ 75,000/µl; hemoglobin ≥ 9 g/dl; anc ≥ 1,000/µl (unsupported by growth factors/transfusions as defined)
Kidney function
egfr ≥ 60 ml/min/1.73m²
Liver function
ast/alt ≤ 3× uln
Cardiac function
lvef ≥ 40% (by echo/muga/cmr)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07410676 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages